{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:44:58Z","timestamp":1794059098023,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41433-025-03980-2","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:39:40Z","timestamp":1757407180000},"page":"2893-2898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy: a comparative study"],"prefix":"10.1038","volume":"39","author":[{"given":"Jaejin","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Yong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-5762","authenticated-orcid":false,"given":"Han Joo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"3980_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125:708\u201324.","journal-title":"Ophthalmology"},{"key":"3980_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/09286580902999413","volume":"16","author":"SJ Song","year":"2009","unstructured":"Song SJ, Youm DJ, Chang Y, Yu HG. Age-related macular degeneration in a screened South Korean population: prevalence, risk factors, and subtypes. Ophthalmic Epidemiol. 2009;16:304\u201310.","journal-title":"Ophthalmic Epidemiol"},{"key":"3980_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453\u201364.","journal-title":"Retina"},{"key":"3980_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","volume":"33","author":"AH Koh","year":"2013","unstructured":"Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33:686\u2013716.","journal-title":"Retina"},{"key":"3980_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","volume":"165","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, et al. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;165:1\u20136.","journal-title":"Am J Ophthalmol"},{"key":"3980_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022;82:825\u201330.","journal-title":"Drugs"},{"key":"3980_CR7","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.2147\/DDDT.S368963","volume":"16","author":"AA Nair","year":"2022","unstructured":"Nair AA, Finn AP, Sternberg P Jr. Spotlight on faricimab in the treatment of wet age-related macular degeneration: design, development and place in therapy. Drug Des Devel Ther. 2022;16:3395\u2013400.","journal-title":"Drug Des Devel Ther"},{"key":"3980_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"3980_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. One-year outcomes and safety assessment of faricimab in treatment-naive patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14:11681.","journal-title":"Sci Rep"},{"key":"3980_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:8747.","journal-title":"Sci Rep"},{"key":"3980_CR11","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1167\/iovs.16-20575","volume":"58","author":"L Ma","year":"2017","unstructured":"Ma L, Brelen ME, Tsujikawa M, Chen H, Chu WK, Lai TY, et al. Identification of ANGPT2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations. Invest Ophthalmol Vis Sci. 2017;58:1076\u201383.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3980_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ajo.2016.03.039","volume":"166","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol. 2016;166:112\u20139.","journal-title":"Am J Ophthalmol"},{"key":"3980_CR13","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1080\/09273948.2021.1931350","volume":"30","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Faricimab: two in the bush is proving better than one in the hand?. Ocul Immunol Inflamm. 2022;30:1961\u20133.","journal-title":"Ocul Immunol Inflamm"},{"key":"3980_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","volume":"30","author":"M Nicolo","year":"2021","unstructured":"Nicolo M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30:193\u2013200.","journal-title":"Expert Opin Investig Drugs"},{"key":"3980_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.65.11.15","volume":"65","author":"T Todoroki","year":"2024","unstructured":"Todoroki T, Takeuchi J, Ota H, Nakano Y, Sajiki AF, Nakamura K, et al. Aqueous humor cytokine analysis in age-related macular degeneration after switching from aflibercept to faricimab. Invest Ophthalmol Vis Sci. 2024;65:15.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3980_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914\u201326.","journal-title":"Ophthalmology"},{"key":"3980_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, et al. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1:100076.","journal-title":"Ophthalmol Sci"},{"key":"3980_CR18","first-page":"1912","volume":"40","author":"A Otani","year":"1999","unstructured":"Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1912\u201320.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3980_CR19","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye. 2023;37:3574\u201381.","journal-title":"Eye"},{"key":"3980_CR20","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s40123-024-01005-x","volume":"13","author":"D Veritti","year":"2024","unstructured":"Veritti D, Sarao V, Gonfiantini M, Rubinato L, Lanzetta P. Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes. Ophthalmol Ther. 2024;13:2813\u201324.","journal-title":"Ophthalmol Ther"},{"key":"3980_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121:1237\u201345.","journal-title":"Ophthalmology"},{"key":"3980_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822\u201332.","journal-title":"Ophthalmology"},{"key":"3980_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06742-2","volume":"12","author":"CH Vyas","year":"2022","unstructured":"Vyas CH, Cheung CMG, Jordan-Yu JMN, Shimizu H, Tan ACS, Sim SS, et al. Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV. Sci Rep. 2022;12:2993.","journal-title":"Sci Rep"},{"key":"3980_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ajo.2006.08.025","volume":"143","author":"A Tsujikawa","year":"2007","unstructured":"Tsujikawa A, Sasahara M, Otani A, Gotoh N, Kameda T, Iwama D, et al. Pigment epithelial detachment in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2007;143:102\u201311.","journal-title":"Am J Ophthalmol"},{"key":"3980_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","volume":"36","author":"BJ Fenner","year":"2022","unstructured":"Fenner BJ, Cheung CMG, Sim SS, Lee WK, Staurenghi G, Lai TYY, et al. Evolving treatment paradigms for PCV. Eye. 2022;36:257\u201365.","journal-title":"Eye"},{"key":"3980_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/jop.2023.0030","volume":"39","author":"HJ Cho","year":"2023","unstructured":"Cho HJ, Kang KH, Yoon W, Lee J, Kim CG, Kim JW. Intravitreal brolucizumab and aflibercept for polypoidal choroidal vasculopathy. J Ocul Pharm Ther. 2023;39:653\u201360.","journal-title":"J Ocul Pharm Ther"},{"key":"3980_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12216-2","volume":"12","author":"A Ito","year":"2022","unstructured":"Ito A, Maruyama-Inoue M, Kitajima Y, Ikeda S, Inoue T, Kadonosono K. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy. Sci Rep. 2022;12:7987.","journal-title":"Sci Rep"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03980-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03980-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03980-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:05:49Z","timestamp":1762171549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03980-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3980"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03980-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}